KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) EBIT (2017 - 2025)

Cardlytics' EBIT history spans 9 years, with the latest figure at -$6.1 million for Q4 2025.

  • For Q4 2025, EBIT rose 26.69% year-over-year to -$6.1 million; the TTM value through Dec 2025 reached -$101.8 million, up 47.92%, while the annual FY2025 figure was -$101.8 million, 47.92% up from the prior year.
  • EBIT reached -$6.1 million in Q4 2025 per CDLX's latest filing, up from -$68.9 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $35.7 million in Q1 2022 to a low of -$382.6 million in Q4 2022.
  • Average EBIT over 5 years is -$50.7 million, with a median of -$21.4 million recorded in 2021.
  • The largest YoY upside for EBIT was 260.84% in 2022 against a maximum downside of 2231.86% in 2022.
  • A 5-year view of EBIT shows it stood at -$16.4 million in 2021, then crashed by 2231.86% to -$382.6 million in 2022, then soared by 73.1% to -$102.9 million in 2023, then surged by 91.92% to -$8.3 million in 2024, then rose by 26.69% to -$6.1 million in 2025.
  • Per Business Quant, the three most recent readings for CDLX's EBIT are -$6.1 million (Q4 2025), -$68.9 million (Q3 2025), and -$12.8 million (Q2 2025).